AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 JUN 12 - (NewsRx.com & NewsRx.net) -- Hormone analogs used in precocious puberty treatment don't harm bone mineral density.
According to a study from Turkey, "the aim of this study was to compare vertebral bone mass values of patients with central precocious puberty (CPP) with healthy age and puberty matched controls and to determine the effect of gonadotropin releasing hormone (GnRH) analogs on bone mass in patients who had been treated at least for 1 year. Girls with idiopathic CPP, 11 pretreatment, 14 post-treatment, and 19 pubertal girls as controls were enrolled in the study."
"The mean ages of the controls and the patients with CPP pre- and post-treatment were 10.25[+ or -]1.06, 8.23[+ or -]1.11, and 10.36[+ or -]1.82 years, respectively. Leuprolide acetate (Lucrin(R)) 3.75 mg was administered s.c. monthly. Bone measurements were performed by dual energy X-ray absorptiometry (DEXA) (Norland) at the anterior-posterior vertebrae (L2-L4)," wrote O. Unal and colleagues, Ankara University.
"The post-treatment group's mean BMD value was 0.66[+ or -]0.12; Z scores according to CA and BA were ...
Source: HighBeam Research, Hormone analogs used in precocious puberty treatment don't harm bone...